We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-7.52%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$250M
AUM Growth
-$48.9M
(-16%)
Cap. Flow
-$2.31M
Cap. Flow
% of AUM
-0.92%
Top 10 Holdings %
Top 10 Hldgs %
27.41%
Holding
148
New
30
Increased
17
Reduced
14
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
|
+$7.25M |
| 2 |
Guardant Health
GH
|
+$5.2M |
| 3 |
STAAR Surgical
STAA
|
+$4.83M |
| 4 |
Inogen
INGN
|
+$4.14M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$3.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$7.56M |
| 2 |
PEPLU
PepperLime Health Acquisition Corporation Unit
PEPLU
|
+$7.23M |
| 3 |
Globus Medical
GMED
|
+$5.83M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$5.82M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.54% |
| 2 | Financials | 11.69% |
| 3 | Industrials | 1.28% |
| 4 | Technology | 0.99% |
| 5 | Consumer Discretionary | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $10.8M | 4.3% |
615,000
+70,000
| +13% | +$1.1M |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $8.43M | 3.37% |
912,000
-538,006
| -37% | -$4.4M |
|
3
ADMA Biologics
ADMA
$2.04B
| $7.92M | 3.17% |
4,000,000
+700,000
| +21% | +$1.38M |
|
|
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
| $7.4M | 2.96% |
1,162,869
-1,333,655
| -53% | -$7.56M |
|
|
PEPL
5
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
| $7.25M | 2.9% |
+735,000
| New | +$7.25M |
|
6
Lantheus
LNTH
$6.68B
| $5.81M | 2.33% |
88,000
+48,000
| +120% | +$3.03M |
|
|
7
STAAR Surgical
STAA
$1.13B
| $5.32M | 2.13% |
+75,000
| New | +$4.83M |
|
8
Insmed
INSM
$22.6B
| $5.29M | 2.11% |
268,000
| – | – |
|
9
Glaukos
GKOS
$8.89B
| $5.18M | 2.07% |
114,000
+20,000
| +21% | +$949K |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $5.16M | 2.07% |
1,750,000
| – | – |
|
|
MBTC
11
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $5.09M | 2.04% |
500,000
| – | – |
|
12
QuidelOrtho
QDEL
$1.14B
| $4.86M | 1.94% |
50,000
-6,000
| -11% | -$612K |
|
13
Inspire Medical Systems
INSP
$1.5B
| $4.38M | 1.75% |
24,000
+8,000
| +50% | +$1.6M |
|
|
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.28M | 1.71% |
75,000
+52,500
| +233% | +$2.98M |
|
|
15
Guardant Health
GH
$19B
| $4.24M | 1.7% |
+105,000
| New | +$5.2M |
|
|
16
CALL
Guardant Health
GH
$19B
| $4.03M | 1.61% |
+100,000
| New | +$4.95M |
|
17
Myriad Genetics
MYGN
$502M
| $4.02M | 1.61% |
221,000
+106,290
| +93% | +$2.21M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $3.96M | 1.59% |
+160,000
| New | +$3.53M |
|
|
EUCR
19
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $3.96M | 1.58% |
400,000
| – | – |
|
|
NVRO
20
DELISTED
NEVRO CORP.
NVRO
| $3.9M | 1.56% |
89,000
+12,000
| +16% | +$660K |
|
21
PUT
Amylyx Pharmaceuticals
AMLX
$2.17B
| $3.85M | 1.54% |
+200,000
| New | +$2.37M |
|
|
AKYA
22
DELISTED
Akoya BioSciences
AKYA
| $3.8M | 1.52% |
+296,000
| New | +$3.07M |
|
|
23
Inogen
INGN
$174M
| $3.77M | 1.51% |
+156,000
| New | +$4.14M |
|
24
Trevi Therapeutics
TRVI
$2.62B
| $3.61M | 1.44% |
+1,284,000
| New | +$3.15M |
|
25
Verastem
VSTM
$547M
| $3.48M | 1.39% |
250,000
+4,083
| +2% | +$65K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Altium Capital Management held 148 positions worth $250M, down 16% from $299M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Altium Capital Management's Q2 2022 filing shows 30 new, 17 increased, 14 reduced and 22 closed positions. Its largest new stake was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M. The largest sale was Esperion Therapeutics, an estimated $7.56M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 78% a quarter earlier, followed by Financials and Industrials.
- Altium Capital Management's largest Q2 2022 buy was PepperLime Health Acquisition Corporation Class A Ordinary Share: 735,000 shares worth $7.25M.
- Altium Capital Management added most to Lantheus in Q2 2022, an estimated $3.03M increase.
- Altium Capital Management's biggest Q2 2022 reduction was Esperion Therapeutics, cutting an estimated $7.56M.
- Altium Capital Management fully exited PepperLime Health Acquisition Corporation Unit in Q2 2022, selling an estimated $7.23M.
- Altium Capital Management's ten largest holdings make up 27% of its $250M portfolio in Q2 2022.
- Altium Capital Management opened 30 new positions and closed 22 in Q2 2022.
- Altium Capital Management's portfolio value fell 16% quarter-over-quarter to $250M.
Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.